Showing results (31-40 of 44) with videos related to
Sort By:
Pageof 5
American Journal of Clinical Pathology|October 15, 2013
Optimizing personalized bone marrow testing using an evidence-based, interdisciplinary team approachAdam C Seegmiller, Annette S Kim, Claudio A Mosse, et al.Blood|March 8, 2019
Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumabJohn C Byrd, Peter Hillmen, Susan O'Brien, et al.British Journal of Haematology|July 30, 2016
Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiableDaniel J Landsburg, Marissa K Falkiewicz, Adam M Petrich, et al.Clinical Lymphoma, Myeloma & Leukemia|September 26, 2018
Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaJacqueline C Barrientos, Susan O'Brien, Jennifer R Brown, et al.Cancer|February 14, 2022
Ofatumumab plus HyperCVAD/HD-MA induction leads to high rates of minimal residual disease negativity in patients with newly diagnosed mantle cell lymphoma: Results of a phase 2 studyPallawi Torka, Othman S Akhtar, Nishitha M Reddy, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 24, 2016
Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow TransplantationMohamed A Kharfan-Dabaja, Ambuj Kumar, Mehdi Hamadani, et al.American Journal of Hematology|November 24, 2016
Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapiesLuciano J Costa, Kami Maddocks, Narendranath Epperla, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 3, 2019
Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303Nancy L Bartlett, Wyndham H Wilson, Sin-Ho Jung, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 12, 2017
Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow TransplantationMohamed A Kharfan-Dabaja, Ambuj Kumar, Ernesto Ayala, et al.The New England Journal of Medicine|June 3, 2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemiaJohn C Byrd, Jennifer R Brown, Susan O'Brien, et al.Pageof 5